IN8bio, Inc. - Common Stock (INAB)
0.1514
-0.0098 (-6.08%)
NASDAQ · Last Trade: Apr 6th, 6:45 PM EDT
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · April 1, 2025

The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill · February 13, 2025

On Wednesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · February 12, 2025

Via Benzinga · February 12, 2025

INAB stock results show that IN8bio missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024

INAB stock results show that IN8bio missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · February 11, 2025

Tuesday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!
Via Chartmill · February 11, 2025

Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · February 11, 2025

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via Chartmill · February 11, 2025

Via Benzinga · October 23, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 21, 2024

Via Benzinga · October 9, 2024

Via Benzinga · October 8, 2024

Via Benzinga · June 14, 2024

Via Benzinga · April 12, 2024

IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targeting leukemia cells while sparing healthy tissue. Experience a potential wider therapeutic window without compromising efficacy.
Via Benzinga · April 10, 2024

Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.
Via Benzinga · April 10, 2024